- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Challenges With PARP Inhibitors in Ovarian Cancer
Kathleen N. Moore, MD, assistant professor in the section of gynecologic oncology and director of the Oklahoma TSET Phase I Clinical Trials Program at the University of Oklahoma Health Sciences Center, discusses challenges with PARP inhibitors in ovarian cancer.